{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": [], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "20391646", "DateCompleted": {"Year": "2010", "Month": "04", "Day": "19"}, "DateRevised": {"Year": "2013", "Month": "11", "Day": "21"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "0097-6326", "JournalIssue": {"Volume": "75", "Issue": "71", "PubDate": {"Year": "2010", "Month": "Apr", "Day": "14"}}, "Title": "Federal register", "ISOAbbreviation": "Fed Regist"}, "ArticleTitle": "Use of ozone-depleting substances; removal of essential-use designation (flunisolide, etc.). Final rule.", "Pagination": {"StartPage": "19213", "EndPage": "19241", "MedlinePgn": "19213-41"}, "Abstract": {"AbstractText": ["The Food and Drug Administration (FDA), after consultation with the Environmental Protection Agency (EPA), is amending FDA's regulation on the use of ozone-depleting substances (ODSs) in self-pressurized containers to remove the essential-use designations for flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil used in oral pressurized metered-dose inhalers (MDIs). The Clean Air Act requires FDA, in consultation with the EPA, to determine whether an FDA-regulated product that releases an ODS is an essential use of the ODS. FDA has concluded that there are no substantial technical barriers to formulating flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil as products that do not release ODSs, and therefore they will no longer be essential uses of ODSs as of the effective dates of this rule. MDIs for these active moieties containing an ODS may not be marketed after the relevant effective date."]}, "AuthorList": [{"AffiliationInfo": [], "Identifier": [], "CollectiveName": "Food and Drug Administration, HHS"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Fed Regist", "NlmUniqueID": "7808722", "ISSNLinking": "0097-6326"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Air Pollutants"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Asthmatic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Bronchodilator Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Chlorofluorocarbons"}, {"RegistryNumber": "0CD5FD6S2M", "NameOfSubstance": "Fluocinolone Acetonide"}, {"RegistryNumber": "1ZK20VI6TY", "NameOfSubstance": "Triamcinolone"}, {"RegistryNumber": "53QOG569E0", "NameOfSubstance": "Metaproterenol"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "GR88G0I6UL", "NameOfSubstance": "Ipratropium"}, {"RegistryNumber": "QF8SVZ843E", "NameOfSubstance": "Albuterol"}], "MeshHeadingList": [{"QualifierName": ["adverse effects", "classification"], "DescriptorName": "Air Pollutants"}, {"QualifierName": ["prevention & control"], "DescriptorName": "Air Pollution"}, {"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Albuterol"}, {"QualifierName": ["administration & dosage", "classification", "therapeutic use"], "DescriptorName": "Anti-Asthmatic Agents"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Asthma"}, {"QualifierName": [], "DescriptorName": "Atmosphere"}, {"QualifierName": ["administration & dosage", "classification", "therapeutic use"], "DescriptorName": "Bronchodilator Agents"}, {"QualifierName": [], "DescriptorName": "Chemistry, Pharmaceutical"}, {"QualifierName": ["administration & dosage", "adverse effects", "classification", "therapeutic use"], "DescriptorName": "Chlorofluorocarbons"}, {"QualifierName": [], "DescriptorName": "Drug Costs"}, {"QualifierName": [], "DescriptorName": "Drug Therapy, Combination"}, {"QualifierName": ["administration & dosage", "analogs & derivatives", "therapeutic use"], "DescriptorName": "Fluocinolone Acetonide"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Ipratropium"}, {"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Metaproterenol"}, {"QualifierName": ["classification"], "DescriptorName": "Nebulizers and Vaporizers"}, {"QualifierName": [], "DescriptorName": "Ozone"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Pulmonary Disease, Chronic Obstructive"}, {"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Triamcinolone"}, {"QualifierName": [], "DescriptorName": "United States"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2010", "Month": "4", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2010", "Month": "4", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2010", "Month": "4", "Day": "20", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["20391646"]}}], "PubmedBookArticle": []}